市場調查報告書
商品編碼
1499509
二十碳五烯酸的全球市場:按來源、形式和應用分類 - 預測(2024-2030)Eicosapentaenoic Acid Market by Source (Algae, Fish, Krill), Form (Ethyl Esters, Triglycerides), Application - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年全球二十碳五烯酸市場規模將達8.625億美元,2024年將達到9.0494億美元,複合年成長率為5.16%,2030年將達到12.2744億美元。
二十碳五烯酸 (EPA) 是一種長鏈Omega-3脂肪酸,主要存在於油性魚類、魚油補充品和某些藻類中。 EPA 市場涵蓋其生產、精製以及在各行業的應用。 EPA 的市場包括藥品、食品、食品和飲料、動物營養品等,強調其多樣化的應用和對最終消費者的好處。生質燃料和生質塑膠等新應用的技術創新正在擴大 EPA 市場的範圍,增加成長和發展的潛力。消費者健康意識的提高以及對天然營養食品的渴望是 EPA 需求的主要驅動力。正在進行的研究證明 EPA 在治療和管理各種健康狀況方面的有效性,支持其在醫學上的應用。鼓勵在食品和膳食食品中使用Omega-3的有利法規將對市場成長產生積極影響。對永續EPA 來源(包括微藻類)的日益關注,為具有環保意識的市場適應提供了重要機會。此外,寵物醫療保健支出的增加預計也將擴大二十碳五烯酸在動物營養領域的應用範圍。
主要市場統計 | |
---|---|
基準年[2023] | 8.625 億美元 |
預測年份 [2024] | 90494萬美元 |
預測年份 [2030] | 12.2744億美元 |
複合年成長率(%) | 5.16% |
區域洞察
由於消費者對 omega-3 營養素的認知度較高且醫療保健產業成熟,美洲成為 EPA 的重要市場。由於重視預防醫學以及人口老化,人們更容易患心血管疾病,該地區對營養食品中所含的EPA的需求強勁。美國在製藥領域佔有重要地位,EPA 廣泛用於治療高三酸甘油脂血症的製劑中。包括 FDA 在內的對Omega-3療法的監管支持進一步鞏固了該地區的市場成長。主要市場參與者的存在,加上積極的行銷策略和有關Omega-3脂肪酸益處的消費者教育,正在推動市場擴張。在健康意識和可支配收入不斷提高的推動下,亞太地區二十碳五烯酸市場正在快速成長,特別是在中國、日本和印度等國家。日本是EPA最大的消費國之一,由於其傳統的多吃魚的飲食習慣,擁有很大的市場佔有率。在該地區,隨著消費者越來越關注預防醫學,對營養食品的需求正在迅速增加。此外,在亞太國家,旨在開發心血管和神經退化性疾病先進治療方法的製藥業的擴張進一步推動了對 EPA 的需求。產品開發的創新,加上水產養殖的發展,特別是重點養殖富含 EPA 的魚類,預計將提升該地區的市場成長潛力。在 EMEA(歐洲、中東和非洲)地區,人們對二十碳五烯酸的興趣正在增加,尤其是在歐洲。人們越來越認知到Omega-3脂肪酸的效用,加上越來越多的老年人口更容易患慢性病,正在推動對富含 EPA 的營養食品的需求。歐洲國家對膳食食品有嚴格的規定,是基於 EPA 的高品質藥品的一個前景看好的市場。由於健康意識的增強和醫療基礎設施的改善,中東和非洲是具有巨大成長潛力的新興市場。雖然歐洲是一個注重創新和嚴格品質標準的成熟市場,但由於經濟多元化和對預防性醫療保健日益成長的興趣,中東和非洲正在提供開拓的機會。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在二十碳五烯酸市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對二十碳五烯酸市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對二十碳五烯酸市場目前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[186 Pages Report] The Eicosapentaenoic Acid Market size was estimated at USD 862.50 million in 2023 and expected to reach USD 904.94 million in 2024, at a CAGR 5.16% to reach USD 1,227.44 million by 2030.
Eicosapentaenoic acid (EPA) is a long-chain omega-3 fatty acid primarily found in oily fish, fish oil supplements, and certain algae. The market for EPA encompasses its production, purification, and applications across various industries. The terrain of the EPA market includes pharmaceuticals, dietary supplements, food & beverages, and animal nutrition, highlighting its diversification in usage and end-consumer benefits. The scope of the EPA market is expanding, with innovation driving into new applications, including biofuels and bioplastics, indicating a broad horizon for growth and development. Growing consumer awareness regarding health and wellness, alongside the desire for natural dietary supplements, significantly drives the demand for EPA. Continuous research substantiating EPA's efficacy in treating and managing various health conditions bolsters its adoption in pharmaceuticals. Favorable regulations encouraging the use of omega-3s in food and dietary supplements positively affect market growth. Growing attention to sustainable sources of EPA, including microalgae, presents a significant opportunity for eco-conscious market adaptation. Additionally, rising pet healthcare expenditures are also expected to boost the scope for eicosapentaenoic acid within animal nutrition segments.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 862.50 million |
Estimated Year [2024] | USD 904.94 million |
Forecast Year [2030] | USD 1,227.44 million |
CAGR (%) | 5.16% |
Regional Insights
The Americas represent a significant market for eicosapentaenoic acid (EPA) owing to the high awareness of omega-3 benefits among consumers and well-established healthcare sectors. The region shows a robust demand for EPA in dietary supplements due to the growing emphasis on preventive healthcare and an aging population prone to cardiovascular diseases. The U.S. holds a significant position in the pharmaceutical sector, where EPA is extensively utilized in formulations aimed at treating conditions including hypertriglyceridemia. The regulatory support from agencies including the FDA for omega-3-based therapeutic products further scaffolds the market growth in this region. The presence of major market players, coupled with aggressive marketing strategies and consumer education on the benefits of omega-3 fatty acids, bolsters the market expansion. The Asia-Pacific region is experiencing rapid growth in the eicosapentaenoic acid market, driven by rising health consciousness and disposable incomes, especially in countries including China, Japan, and India. Japan, being one of the largest consumers of EPA, holds a significant market share due to its traditional diet rich in fish. The region is witnessing a surge in the demand for dietary supplements as consumers are increasingly inclined towards preventive healthcare measures. Additionally, the expansion of the pharmaceutical sector in APAC countries, aimed at developing advanced treatment options for cardiovascular and neurodegenerative diseases, further propels the demand for EPA. Innovation in product development, coupled with an increase in the aquaculture industry, specifically focusing on EPA-rich fish farming, is set to boost the market's growth potential in this region. The EMEA region exhibits a growing interest in Eicosapentaenoic Acid, with Europe leading the charge. The increasing awareness about the benefits of omega-3 fatty acids, coupled with a rising elderly population susceptible to chronic diseases, fuels the demand for EPA-enriched dietary supplements. European countries, with their stringent regulatory frameworks for nutritional products, present a promising market for high-quality, EPA-based pharmaceuticals. The Middle East and Africa are emerging markets with vast growth potential, attributed to a gradual shift towards health and wellness trends and improving healthcare infrastructure. While Europe's mature market focuses on innovation and stringent quality standards, the Middle East and Africa offer untapped opportunities driven by economic diversification and an increasing focus on preventive healthcare.
Market Insights
The market dynamics represent an ever-changing landscape of the Eicosapentaenoic Acid Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Eicosapentaenoic Acid Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Eicosapentaenoic Acid Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
Amneal Pharmaceuticals, Inc. and Strides Pharma Science Limited announced their strategic collaboration for the introduction of Icosapent Ethyl soft gel capsules, a VASCEPA reference product. This innovative product, available in 0.5g and 1g dosages, is an adjunctive treatment to dietary adjustments to lower triglyceride levels in adults with severe hypertriglyceridemia (>=500 mg/dL). [Published On: 2023-12-01]
Biomar Forms Partnership to Commercialise Omega-3 Camelina
BioMar, a producer of salmon feed, entered into a strategic partnership with Yield10 Bioscience, a U.S.-based company, to bring to market a revolutionary genetically modified oilseed crop rich in omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), matching the levels found in traditional fish oil. This innovation presents a land-based, sustainable alternative for sourcing omega-3s, essential components in aquaculture feeds. [Published On: 2023-10-31]
Amarin and Neopharm Announce Exclusive Commercialization Agreement for Vazkepa (Icosapent Ethyl) in Israel
Amarin Corporation plc and Neopharm Israel officially announced their exclusive partnership for the marketing and commercializing of VAZKEPA (icosapent ethyl) in Israel, Gaza, the West Bank, and territories under the Palestinian Authority. VAZKEPA capsules, featuring icosapent ethyl as their sole active ingredient-a highly purified form of eicosapentaenoic acid-represent the first prescription therapy of its kind. This strategic alliance leverages Neopharm's significant expertise and strong presence in cardiology to ensure VAZKEPA's accessibility to patients in need, especially those at elevated cardiovascular risk. [Published On: 2023-08-08]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Eicosapentaenoic Acid Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Eicosapentaenoic Acid Market, highlighting leading vendors and their innovative profiles. These include AlgiSys BioSciences Inc., Archer Daniels Midland Company, Arctic Nutrition AG, Asterisk Laboratories (I) Pvt. Ltd., BASF SE, BIOSEARCH, SA, Cayman Chemical Company, Corbion N.V., Croda International PLC, Epax Norway AS, Evonik Industries AG, Golden Omega S.A., Indo Rama Engineers, KD Pharma Group, Koninklijke DSM N.V., Novasep Holding SAS, Novotech Nutraceuticals, Inc., Omega Protein Corporation, Orkla Health AS, Pelagia AS, Santa Cruz Biotechnology, Inc., Shandong Yuwang Pharmaceutical Co., Ltd., SimSon Pharma Limited, Sinomega Biotech Engineering Co.,Ltd., and Toronto Research Chemicals Inc..
Market Segmentation & Coverage